

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, DC. 20201
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/936,362	12/19/2001	Sheena M. Loosmore	1038-1190 MIS:jb	3637
24223 7	590 03/26/2003			
SIM & MCBURNEY 330 UNIVERSITY AVENUE 6TH FLOOR TORONTO, ON M5G 1R7			EXAMINER	
			GRASER, JENNIFER E	
CANADA			ART UNIT	PAPER NUMBER
			1645	7
			DATE MAILED: 03/26/2003	, (

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. 09/936,362

Applicant(s)

Loosmore et al.

Examiner

Jennifer Graser

Art Unit **1645** 



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address
A SHO	for Reply ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. Usings of time may be available under the provisions of 37 C	TTO EXPIRE MONTH(S) FROM  CFR 1.136 (a). In no event, however, may a reply be timely filed
aft - If the be - If NO co - Failur - Any r	ter SIX (6) MONTHS from the mailing date of this communic period for reply specified above is less than thirty (30) days considered timely. period for reply is specified above, the maximum statutory mmunication. The to reply within the set or extended period for reply will, but	
Status	med patent term adjustment. See of GTT 1.704(6).	,
1) 🗆	Responsive to communication(s) filed on	
2a) 🗌	This action is <b>FINAL</b> . 2b) 💢 This ac	ction is non-final.
3) 🗆	Since this application is in condition for allowance closed in accordance with the practice under Ex pa	except for formal matters, prosecution as to the merits is arte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposi	tion of Claims	
4) 💢	Claim(s) <u>1-29</u>	is/are pending in the application.
4	la) Of the above, claim(s)	is/are withdrawn from consideratio
5) 🗆	Claim(s)	is/are allowed.
6) 🗆	Claim(s)	is/are rejected.
7) 🗆	Claim(s)	is/are objected to.
8) 💢	Claims <u>1-29</u>	are subject to restriction and/or election requirement
Applica	ntion Papers	
9) 🗆	The specification is objected to by the Examiner.	
10)	The drawing(s) filed on is/a	are objected to by the Examiner.
11)□	The proposed drawing correction filed on	is: all approved the disapproved.
12)	The oath or declaration is objected to by the Exam	niner.
	under 35 U.S.C. § 119 Acknowledgement is made of a claim for foreign p	priority under 35 U.S.C. § 119(a)-(d).
a) [	☐ All b)☐ Some* c)☐ None of:	
	1. Certified copies of the priority documents have	
		ve been received in Application No
	<ol> <li>Copies of the certified copies of the priority of application from the International Bure ee the attached detailed Office action for a list of the action for a l</li></ol>	
14)	Acknowledgement is made of a claim for domestic	
Attachm	ent(s)	
15) 🔲 N	otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).
16) Notice of Draftsperson's Patent Drawing Review (PTO-948)		19) Notice of Informal Patent Application (PTO-152)
17) 🔲 In	formation Disclosure Statement(s) (PTO-1449) Paper No(s)	20) Other:

Application/Control Number: 09/936,362

Art Unit: 1645

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-14, 23-27 and 29, drawn to isolated polynucleotides, host cells and vectors comprising said polynucleotides and methods of using said polynucleotides to produce proteins. *NOTE:* Applicants must choose only one DNA to be searched, for example SEQ ID NO:23 and a the corresponding DNA which encodes the protein of SEQ ID NO:24 and their corresponding primers. This is not a species election, but is a restriction because each DNA sequence represents a completely different product.

Group II, claim(s) 16-22 (only as they pertain to Parts A-C of claim 16), drawn to immunogenic compositions comprising polynucleotides and methods of inducing protection against disease through the administration of said polynucleotides. *NOTE:* Applicants must choose only one immunogenic composition to be searched, for example SEQ ID NO:23 and a the corresponding DNA which encodes the protein of SEQ ID NO:24 and their corresponding primers. This is not a species election, but is a restriction because each DNA sequence represents a completely different product.

Application/Control Number: 09/936,362

Art Unit: 1645

Group III, claim(s)15, drawn to a polypeptide. *NOTE:* Applicants must choose only one protein to be searched. This is not a species election, but is a restriction because each amino acid sequence represents a completely different product.

Group IV, claim(s) 16-22 (only as they pertain to Part D of claim 16), drawn to immunogenic compositions comprising a polypeptide and methods of inducing protection against disease through the administration of said polypeptide. *NOTE:* Applicants must choose only one immunogenic composition to be searched. This is not a species election, but is a restriction because each amino acid sequence represents a completely different product.

2. The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I-IV lack the same or corresponding special technical feature because they each contain different products. Group I's special technical feature, a polynucleotide, is biologically, chemically and structurally different than Group III's special technical feature which is a polypeptide. Group II contains methods of protection with an immunogenic composition that is different from Group I since it contains a pharmaceutically acceptable carrier. Further, Group I's polynucleotides may be used for purposes other than as immunogens, i.e, they may be used in hybridization assays. Group IV comprises methods of protection using an immunogenic composition comprising a polypeptide and a pharmaceutically acceptable carrier. The

Application/Control Number: 09/936,362

Art Unit: 1645

polypeptide of Group III may be used for purposes other than as immunogens, i.e, they may be used in detction assays. Accordingly, Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features.

3. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15,1989). The Group 1645 Fax number is (703) 308-4242 which is able to receive transmissions 24 hours/day, 7 days/week.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer E. Graser whose telephone number is (703) 308-1742. The examiner can normally be reached on Monday-Friday from 7:00 AM-4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached on (703) 308-3909.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JENNIFER E. GRASER

PRIMARY EXAM